Jenburkt Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 11-07-2024
- Paid Up Capital ₹ 4.41 Cr
as on 11-07-2024
- Company Age 39 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.80 Cr
as on 11-07-2024
- Satisfied Charges ₹ 11.41 Cr
as on 11-07-2024
- Revenue 10.04%
(FY 2023)
- Profit 10.36%
(FY 2023)
- Ebitda 11.42%
(FY 2023)
- Net Worth 4.27%
(FY 2023)
- Total Assets -0.80%
(FY 2023)
About Jenburkt Pharmaceuticals
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524731.
The Corporate was formerly known as Jen Burkt Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 4.41 Cr.
The company currently has active open charges totaling ₹6.80 Cr. The company has closed loans amounting to ₹11.41 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Jenburkt Pharmaceuticals Ltd India are Dilip Bhuta as CFO and Ashish Shah as Company Secretary. Bharat Bhate, Rameshchandra Vora, Arun Raskapurwala, and Four other members serve as directors at the Company.
- CIN/LLPIN
L24230MH1985PLC036541
- Company No.
036541
- Stock Symbol
BSE : 524731
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 Jun 1985
- Date of AGM
26 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Jenburkt Pharmaceuticals Ltd offer?
Jenburkt Pharmaceuticals Ltd offers a wide range of products and services, including Diabetic Medicines, Vitamins, Minerals & Antioxidants.
Who are the key members and board of directors at Jenburkt Pharmaceuticals?
Executive Team (3)
AB
Ashish Bhuta
Managing DirectorAppointment Date: 02-Jun-2007
Status: Current
DB
Dilip Bhuta CFOAppointment Date: 30-May-2014
Status: Current
AS
Ashish Shah Company SecretaryAppointment Date: 01-Dec-1999
Status: Current
Board Members(6)
Financial Performance and Corporate Structure Insights of Jenburkt Pharmaceuticals.
Jenburkt Pharmaceuticals Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 10.04% increase. The company also saw a substantial improvement in profitability, with a 10.36% increase in profit. The company's net worth moved up by a moderate rise of 4.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jenburkt Pharmaceuticals?
In 2023, Jenburkt Pharmaceuticals had a promoter holding of 47.56% and a public holding of 52.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bhuta Holdings Private Limited
Active
42 years 7 months Ashish Bhuta and Dilip Bhuta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Nov 2022 | ₹0.10 M | Open |
Others Creation Date: 21 Nov 2022 | ₹0.20 M | Open |
Others Creation Date: 21 Nov 2022 | ₹2.00 Cr | Open |
How Many Employees Work at Jenburkt Pharmaceuticals?
Jenburkt Pharmaceuticals has a workforce of 765 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jenburkt Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jenburkt Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
